These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 32615261)
1. Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent. Uram Ł; Markowicz J; Misiorek M; Filipowicz-Rachwał A; Wołowiec S; Wałajtys-Rode E Eur J Pharm Sci; 2020 Sep; 152():105439. PubMed ID: 32615261 [TBL] [Abstract][Full Text] [Related]
2. The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARγ Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro. Uram Ł; Misiorek M; Pichla M; Filipowicz-Rachwał A; Markowicz J; Wołowiec S; Wałajtys-Rode E Molecules; 2019 Oct; 24(20):. PubMed ID: 31652556 [TBL] [Abstract][Full Text] [Related]
3. Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents-Comparative Studies on Normal and Immortalized Cell Lines, and on Uram Ł; Pieńkowska N; Misiorek M; Szymaszek Ż; Twardowska M; Siorek M; Wołowiec S Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542198 [TBL] [Abstract][Full Text] [Related]
4. Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and/or Fmoc-l-Leucine and its cytotoxicity for normal and cancer human cell lines. Uram Ł; Filipowicz A; Misiorek M; Pieńkowska N; Markowicz J; Wałajtys-Rode E; Wołowiec S Eur J Pharm Sci; 2018 Nov; 124():1-9. PubMed ID: 30118847 [TBL] [Abstract][Full Text] [Related]
5. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456 [TBL] [Abstract][Full Text] [Related]
6. Biotin Transport-Targeting Polysaccharide-Modified PAMAM G3 Dendrimer as System Delivering α-Mangostin into Cancer Cells and Markowicz J; Uram Ł; Wołowiec S; Rode W Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884739 [TBL] [Abstract][Full Text] [Related]
7. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway. Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and Different Effects of Biotinylated PAMAM G3 Dendrimer Substituted with Nimesulide in Human Normal Fibroblasts and Squamous Carcinoma Cells. Uram Ł; Filipowicz-Rachwał A; Misiorek M; Winiarz A; Wałajtys-Rode E; Wołowiec S Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31480608 [TBL] [Abstract][Full Text] [Related]
9. COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells. Majchrzak-Celińska A; Misiorek JO; Kruhlenia N; Przybyl L; Kleszcz R; Rolle K; Krajka-Kuźniak V BMC Cancer; 2021 May; 21(1):493. PubMed ID: 33941107 [TBL] [Abstract][Full Text] [Related]
10. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species. Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068 [TBL] [Abstract][Full Text] [Related]
11. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
12. Lucanthone, a Potential PPT1 Inhibitor, Perturbs Stemness, Reduces Tumor Microtube Formation, and Slows the Growth of Temozolomide-Resistant Gliomas In Vivo. Radin DP; Shifman S; Outhwaite IR; Sharma A; Bases R; Seeliger MA; Tsirka SE J Pharmacol Exp Ther; 2024 Mar; 389(1):51-60. PubMed ID: 38296645 [TBL] [Abstract][Full Text] [Related]
13. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists. Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057 [TBL] [Abstract][Full Text] [Related]
14. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406 [TBL] [Abstract][Full Text] [Related]
15. The Importance of Biotinylation for the Suitability of Cationic and Neutral Fourth-Generation Polyamidoamine Dendrimers as Targeted Drug Carriers in the Therapy of Glioma and Liver Cancer. Uram Ł; Twardowska M; Szymaszek Ż; Misiorek M; Łyskowski A; Setkowicz Z; Rauk Z; Wołowiec S Molecules; 2024 Sep; 29(18):. PubMed ID: 39339289 [TBL] [Abstract][Full Text] [Related]
16. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition. Liu T; Li A; Xu Y; Xin Y Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175 [TBL] [Abstract][Full Text] [Related]
17. Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism. Yin D; Jin G; He H; Zhou W; Fan Z; Gong C; Zhao J; Xiong H Aging (Albany NY); 2021 Sep; 13(17):21268-21282. PubMed ID: 34497154 [TBL] [Abstract][Full Text] [Related]
18. PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma. Li PC; Chen SY; Xiangfei D; Mao C; Wu CH; Shih JC BMC Complement Med Ther; 2020 Aug; 20(1):252. PubMed ID: 32799864 [TBL] [Abstract][Full Text] [Related]
19. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952 [TBL] [Abstract][Full Text] [Related]
20. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]